Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures.

Clinical medicine insights. Reproductive health

García-Ferreyra J, Hilario R, Luna D, Villegas L, Romero R, Zavala P, Dueñas-Chacón J.
PMID: 26085790
Clin Med Insights Reprod Health. 2015 Jun 10;9:7-11. doi: 10.4137/CMRH.S25494. eCollection 2015.

CAPSULE: Clinical outcomes using INVOcell device with ICSI.OBJECTIVE: Intravaginal culture of oocytes (INVO) procedure is an intravaginal culture system that utilizes the INVOcell device in which the fertilization and embryo culture occur. In this procedure, the vaginal cavity serves...

Cite
García-Ferreyra J, Hilario R, Luna D, et al. In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures. Clin Med Insights Reprod Health. 2015;9:7-11doi: 10.4137/CMRH.S25494.
García-Ferreyra, J., Hilario, R., Luna, D., Villegas, L., Romero, R., Zavala, P., & Dueñas-Chacón, J. (2015). In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures. Clinical medicine insights. Reproductive health, 97-11. https://doi.org/10.4137/CMRH.S25494
García-Ferreyra, Javier, et al. "In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures." Clinical medicine insights. Reproductive health vol. 9 (2015): 7-11. doi: https://doi.org/10.4137/CMRH.S25494
García-Ferreyra J, Hilario R, Luna D, Villegas L, Romero R, Zavala P, Dueñas-Chacón J. In Vivo Culture System Using the INVOcell Device Shows Similar Pregnancy and Implantation Rates to Those Obtained from In Vivo Culture System in ICSI Procedures. Clin Med Insights Reprod Health. 2015 Jun 10;9:7-11. doi: 10.4137/CMRH.S25494. eCollection 2015. PMID: 26085790; PMCID: PMC4463795.
Copy Download .nbib Format: NLM
Management of Vaginal Atrophy: Implications from the REVIVE Survey.

Clinical medicine insights. Reproductive health

Wysocki S, Kingsberg S, Krychman M.
PMID: 24987271
Clin Med Insights Reprod Health. 2014 Jun 08;8:23-30. doi: 10.4137/CMRH.S14498. eCollection 2014.

Vulvar and vaginal atrophy (VVA) is a chronic and progressive medical condition common in postmenopausal women. Symptoms of VVA such as dyspareunia, vaginal dryness, irritation, and itching can negatively impact sexual function and quality of life. The REVIVE (REal...

Cite
Wysocki S, Kingsberg S, Krychman M. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014;8:23-30doi: 10.4137/CMRH.S14498.
Wysocki, S., Kingsberg, S., & Krychman, M. (2014). Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clinical medicine insights. Reproductive health, 823-30. https://doi.org/10.4137/CMRH.S14498
Wysocki, Susan, et al. "Management of Vaginal Atrophy: Implications from the REVIVE Survey." Clinical medicine insights. Reproductive health vol. 8 (2014): 23-30. doi: https://doi.org/10.4137/CMRH.S14498
Wysocki S, Kingsberg S, Krychman M. Management of Vaginal Atrophy: Implications from the REVIVE Survey. Clin Med Insights Reprod Health. 2014 Jun 08;8:23-30. doi: 10.4137/CMRH.S14498. eCollection 2014. PMID: 24987271; PMCID: PMC4071759.
Copy Download .nbib Format: NLM
High Aneuploidy Rates Observed in Embryos Derived from Donated Oocytes are Related to Male Aging and High Percentages of Sperm DNA Fragmentation.

Clinical medicine insights. Reproductive health

García-Ferreyra J, Luna D, Villegas L, Romero R, Zavala P, Hilario R, Dueñas-Chacón J.
PMID: 26604851
Clin Med Insights Reprod Health. 2015 Nov 11;9:21-7. doi: 10.4137/CMRH.S32769. eCollection 2015.

CAPSULE: Male aging effects on aneuploidy rates in embryos.OBJECTIVE: Paternal age is associated with decreasing sperm quality; however, it is unknown if it influences chromosomal abnormalities in embryos. The objective of this study is to evaluate if the aneuploidy...

Cite
García-Ferreyra J, Luna D, Villegas L, et al. High Aneuploidy Rates Observed in Embryos Derived from Donated Oocytes are Related to Male Aging and High Percentages of Sperm DNA Fragmentation. Clin Med Insights Reprod Health. 2015;9:21-7doi: 10.4137/CMRH.S32769.
García-Ferreyra, J., Luna, D., Villegas, L., Romero, R., Zavala, P., Hilario, R., & Dueñas-Chacón, J. (2015). High Aneuploidy Rates Observed in Embryos Derived from Donated Oocytes are Related to Male Aging and High Percentages of Sperm DNA Fragmentation. Clinical medicine insights. Reproductive health, 921-7. https://doi.org/10.4137/CMRH.S32769
García-Ferreyra, Javier, et al. "High Aneuploidy Rates Observed in Embryos Derived from Donated Oocytes are Related to Male Aging and High Percentages of Sperm DNA Fragmentation." Clinical medicine insights. Reproductive health vol. 9 (2015): 21-7. doi: https://doi.org/10.4137/CMRH.S32769
García-Ferreyra J, Luna D, Villegas L, Romero R, Zavala P, Hilario R, Dueñas-Chacón J. High Aneuploidy Rates Observed in Embryos Derived from Donated Oocytes are Related to Male Aging and High Percentages of Sperm DNA Fragmentation. Clin Med Insights Reprod Health. 2015 Nov 11;9:21-7. doi: 10.4137/CMRH.S32769. eCollection 2015. PMID: 26604851; PMCID: PMC4642825.
Copy Download .nbib Format: NLM
The participation of prospective fathers in preconception care.

Clinical medicine insights. Reproductive health

Czeizel AE, Czeizel B, Vereczkey A.
PMID: 24453513
Clin Med Insights Reprod Health. 2013 Jan 22;7:1-9. doi: 10.4137/CMRH.S10930. eCollection 2013 Jan 22.

We present the data of male participants in the Coordinating Center of the Hungarian Preconception Service (HPS), Budapest, 1984-2010. One of main objectives of the HPS was the incorporation of male partners of female participants into the preparation of...

Cite
Czeizel AE, Czeizel B, Vereczkey A. The participation of prospective fathers in preconception care. Clin Med Insights Reprod Health. 2013;7:1-9doi: 10.4137/CMRH.S10930.
Czeizel, A. E., Czeizel, B., & Vereczkey, A. (2013). The participation of prospective fathers in preconception care. Clinical medicine insights. Reproductive health, 71-9. https://doi.org/10.4137/CMRH.S10930
Czeizel, Andrew E, et al. "The participation of prospective fathers in preconception care." Clinical medicine insights. Reproductive health vol. 7 (2013): 1-9. doi: https://doi.org/10.4137/CMRH.S10930
Czeizel AE, Czeizel B, Vereczkey A. The participation of prospective fathers in preconception care. Clin Med Insights Reprod Health. 2013 Jan 22;7:1-9. doi: 10.4137/CMRH.S10930. eCollection 2013 Jan 22. PMID: 24453513; PMCID: PMC3888083.
Copy Download .nbib Format: NLM
Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.

Clinical medicine insights. Reproductive health

Marder W, Fisseha S, Ganser MA, Somers EC.
PMID: 23970822
Clin Med Insights Reprod Health. 2012 Oct 24;2012(6):9-18. doi: 10.4137/CMRH.S10415.

Women with autoimmune diseases such as lupus, scleroderma, and vasculitis receiving cyclophosphamide for severe disease manifestations risk primary ovarian insufficiency(POI) due to gonadotoxicity of this therapy. In addition to loss of reproductive potential, POI is associated with increased risk...

Cite
Marder W, Fisseha S, Ganser MA, et al. Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. Clin Med Insights Reprod Health. 2012;2012(6):9-18doi: 10.4137/CMRH.S10415.
Marder, W., Fisseha, S., Ganser, M. A., & Somers, E. C. (2012). Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. Clinical medicine insights. Reproductive health, 2012(6), 9-18. https://doi.org/10.4137/CMRH.S10415
Marder, Wendy, et al. "Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility." Clinical medicine insights. Reproductive health vol. 2012,6 (2012): 9-18. doi: https://doi.org/10.4137/CMRH.S10415
Marder W, Fisseha S, Ganser MA, Somers EC. Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. Clin Med Insights Reprod Health. 2012 Oct 24;2012(6):9-18. doi: 10.4137/CMRH.S10415. PMID: 23970822; PMCID: PMC3747568.
Copy Download .nbib Format: NLM
The Low Prevalence of Y Chromosomal Microdeletions is Observed in the Oligozoospermic Men in the Area of Mato Grosso State and Amazonian Region of Brazilian Patients.

Clinical medicine insights. Reproductive health

Dos Santos Godoy GC, Galera BB, Araujo C, Barbosa JS, de Pinho MF, Galera MF, de Medeiros SF.
PMID: 25210487
Clin Med Insights Reprod Health. 2014 Aug 11;8:51-7. doi: 10.4137/CMRH.S15475. eCollection 2014.

OBJECTIVE: To determine the prevalence of chromosomal abnormalities and microdeletions on Y chromosome in infertile patients with oligozoospermia or azoospermia in Mato Grosso state, Brazil.METHODS: This cross-sectional study enrolled 94 men from infertile couples. Karyotype analysis was performed by...

Cite
Dos Santos Godoy GC, Galera BB, Araujo C, et al. The Low Prevalence of Y Chromosomal Microdeletions is Observed in the Oligozoospermic Men in the Area of Mato Grosso State and Amazonian Region of Brazilian Patients. Clin Med Insights Reprod Health. 2014;8:51-7doi: 10.4137/CMRH.S15475.
Dos Santos Godoy, G. C., Galera, B. B., Araujo, C., Barbosa, J. S., de Pinho, M. F., Galera, M. F., & de Medeiros, S. F. (2014). The Low Prevalence of Y Chromosomal Microdeletions is Observed in the Oligozoospermic Men in the Area of Mato Grosso State and Amazonian Region of Brazilian Patients. Clinical medicine insights. Reproductive health, 851-7. https://doi.org/10.4137/CMRH.S15475
Dos Santos Godoy, Gleice Cristina, et al. "The Low Prevalence of Y Chromosomal Microdeletions is Observed in the Oligozoospermic Men in the Area of Mato Grosso State and Amazonian Region of Brazilian Patients." Clinical medicine insights. Reproductive health vol. 8 (2014): 51-7. doi: https://doi.org/10.4137/CMRH.S15475
Dos Santos Godoy GC, Galera BB, Araujo C, Barbosa JS, de Pinho MF, Galera MF, de Medeiros SF. The Low Prevalence of Y Chromosomal Microdeletions is Observed in the Oligozoospermic Men in the Area of Mato Grosso State and Amazonian Region of Brazilian Patients. Clin Med Insights Reprod Health. 2014 Aug 11;8:51-7. doi: 10.4137/CMRH.S15475. eCollection 2014. PMID: 25210487; PMCID: PMC4133943.
Copy Download .nbib Format: NLM
Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience.

Clinical medicine insights. Reproductive health

Hendawy SF, Abdel-Mohsen D, Ebrahim SE, Ewais H, Moussa SH, Khattab DA, Mohamed NA, Samaha HE.
PMID: 24453508
Clin Med Insights Reprod Health. 2011 May 12;5:17-24. doi: 10.4137/CMRH.S6862. eCollection 2011 May 12.

BACKGROUND: Systemic Lupus Erythematosus (SLE) has a tendency to occur in women in their reproductive years, causing complications during pregnancy and labour. Conversely, pregnancy can cause flares of disease activity, often necessitating immediate intervention.AIM OF STUDY: to study pregnancy...

Cite
Hendawy SF, Abdel-Mohsen D, Ebrahim SE, et al. Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience. Clin Med Insights Reprod Health. 2011;5:17-24doi: 10.4137/CMRH.S6862.
Hendawy, S. F., Abdel-Mohsen, D., Ebrahim, S. E., Ewais, H., Moussa, S. H., Khattab, D. A., Mohamed, N. A., & Samaha, H. E. (2011). Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience. Clinical medicine insights. Reproductive health, 517-24. https://doi.org/10.4137/CMRH.S6862
Hendawy, S F, et al. "Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience." Clinical medicine insights. Reproductive health vol. 5 (2011): 17-24. doi: https://doi.org/10.4137/CMRH.S6862
Hendawy SF, Abdel-Mohsen D, Ebrahim SE, Ewais H, Moussa SH, Khattab DA, Mohamed NA, Samaha HE. Pregnancy related complications in patients with systemic lupus erythematosus, an egyptian experience. Clin Med Insights Reprod Health. 2011 May 12;5:17-24. doi: 10.4137/CMRH.S6862. eCollection 2011 May 12. PMID: 24453508; PMCID: PMC3888067.
Copy Download .nbib Format: NLM
Seroprevalences and Correlates of Hepatitis B and C Among Cameroonian Pregnant Women.

Clinical medicine insights. Reproductive health

Fouelifack FY, Fouedjio JH, Fouogue JT, Fouelifa LD.
PMID: 29692639
Clin Med Insights Reprod Health. 2018 Apr 16;12:1179558118770671. doi: 10.1177/1179558118770671. eCollection 2018.

BACKGROUND AND RATIONALE: Viral hepatitis B (VHB) and viral hepatitis C (VHC) are major public health issues in resource-poor countries where vertical transmission remains high.AIM: To assess prevalences and correlates of VHB and VHC among women attending antenatal clinic.METHODS:...

Cite
Fouelifack FY, Fouedjio JH, Fouogue JT, et al. Seroprevalences and Correlates of Hepatitis B and C Among Cameroonian Pregnant Women. Clin Med Insights Reprod Health. 2018;12:1179558118770671doi: 10.1177/1179558118770671.
Fouelifack, F. Y., Fouedjio, J. H., Fouogue, J. T., & Fouelifa, L. D. (2018). Seroprevalences and Correlates of Hepatitis B and C Among Cameroonian Pregnant Women. Clinical medicine insights. Reproductive health, 121179558118770671. https://doi.org/10.1177/1179558118770671
Fouelifack, Florent Ymele, et al. "Seroprevalences and Correlates of Hepatitis B and C Among Cameroonian Pregnant Women." Clinical medicine insights. Reproductive health vol. 12 (2018): 1179558118770671. doi: https://doi.org/10.1177/1179558118770671
Fouelifack FY, Fouedjio JH, Fouogue JT, Fouelifa LD. Seroprevalences and Correlates of Hepatitis B and C Among Cameroonian Pregnant Women. Clin Med Insights Reprod Health. 2018 Apr 16;12:1179558118770671. doi: 10.1177/1179558118770671. eCollection 2018. PMID: 29692639; PMCID: PMC5909852.
Copy Download .nbib Format: NLM
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review.

Clinical medicine insights. Reproductive health

Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Buzzatti G, Molinelli C, Boccardo F, Del Mastro L.
PMID: 31391786
Clin Med Insights Reprod Health. 2019 Jul 31;13:1179558119864584. doi: 10.1177/1179558119864584. eCollection 2019.

The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced premature ovarian failure. Pharmacological temporary ovarian suppression obtained with the gonadotropin-releasing hormone agonist (GnRHa) administered concomitantly with chemotherapy has been investigated as a technique capable to reduce...

Cite
Poggio F, Lambertini M, Bighin C, et al. Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. Clin Med Insights Reprod Health. 2019;13:1179558119864584doi: 10.1177/1179558119864584.
Poggio, F., Lambertini, M., Bighin, C., Conte, B., Blondeaux, E., D'Alonzo, A., Dellepiane, C., Buzzatti, G., Molinelli, C., Boccardo, F., & Del Mastro, L. (2019). Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. Clinical medicine insights. Reproductive health, 131179558119864584. https://doi.org/10.1177/1179558119864584
Poggio, Francesca, et al. "Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review." Clinical medicine insights. Reproductive health vol. 13 (2019): 1179558119864584. doi: https://doi.org/10.1177/1179558119864584
Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Buzzatti G, Molinelli C, Boccardo F, Del Mastro L. Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review. Clin Med Insights Reprod Health. 2019 Jul 31;13:1179558119864584. doi: 10.1177/1179558119864584. eCollection 2019. PMID: 31391786; PMCID: PMC6669835.
Copy Download .nbib Format: NLM
Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy.

Clinical medicine insights. Reproductive health

Blumenfeld Z.
PMID: 31488958
Clin Med Insights Reprod Health. 2019 Aug 21;13:1179558119870163. doi: 10.1177/1179558119870163. eCollection 2019.

The only clinically accepted method of fertility preservation in young women facing gonadotoxic chemo- and/or radiotherapy for malignant or autoimmune diseases is cryopreservation of embryos or unfertilized ova, whereas cryopreservation of ovarian tissue for future reimplantation, or in vitro...

Cite
Blumenfeld Z. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. Clin Med Insights Reprod Health. 2019;13:1179558119870163doi: 10.1177/1179558119870163.
Blumenfeld, Z. (2019). Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. Clinical medicine insights. Reproductive health, 131179558119870163. https://doi.org/10.1177/1179558119870163
Blumenfeld, Zeev. "Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy." Clinical medicine insights. Reproductive health vol. 13 (2019): 1179558119870163. doi: https://doi.org/10.1177/1179558119870163
Blumenfeld Z. Fertility Preservation Using GnRH Agonists: Rationale, Possible Mechanisms, and Explanation of Controversy. Clin Med Insights Reprod Health. 2019 Aug 21;13:1179558119870163. doi: 10.1177/1179558119870163. eCollection 2019. PMID: 31488958; PMCID: PMC6710670.
Copy Download .nbib Format: NLM
Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?.

Clinical medicine insights. Reproductive health

Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C.
PMID: 30886529
Clin Med Insights Reprod Health. 2019 Mar 09;13:1179558119828393. doi: 10.1177/1179558119828393. eCollection 2019.

Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasing hormone agonist (GnRHa) during...

Cite
Lambertini M, Richard F, Nguyen B, et al. Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. Clin Med Insights Reprod Health. 2019;13:1179558119828393doi: 10.1177/1179558119828393.
Lambertini, M., Richard, F., Nguyen, B., Viglietti, G., & Villarreal-Garza, C. (2019). Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. Clinical medicine insights. Reproductive health, 131179558119828393. https://doi.org/10.1177/1179558119828393
Lambertini, Matteo, et al. "Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?." Clinical medicine insights. Reproductive health vol. 13 (2019): 1179558119828393. doi: https://doi.org/10.1177/1179558119828393
Lambertini M, Richard F, Nguyen B, Viglietti G, Villarreal-Garza C. Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?. Clin Med Insights Reprod Health. 2019 Mar 09;13:1179558119828393. doi: 10.1177/1179558119828393. eCollection 2019. PMID: 30886529; PMCID: PMC6410390.
Copy Download .nbib Format: NLM
Pathogenesis and Consequences of Disordered Sleep in PCOS.

Clinical medicine insights. Reproductive health

Sam S, Ehrmann DA.
PMID: 31516314
Clin Med Insights Reprod Health. 2019 Sep 03;13:1179558119871269. doi: 10.1177/1179558119871269. eCollection 2019.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder that is characterized by hyperandrogenism and menstrual irregularity. Affected women have a high prevalence of insulin resistance and related metabolic complications. The frequency of sleep disturbances appears to be increased...

Cite
Sam S, Ehrmann DA. Pathogenesis and Consequences of Disordered Sleep in PCOS. Clin Med Insights Reprod Health. 2019;13:1179558119871269doi: 10.1177/1179558119871269.
Sam, S., & Ehrmann, D. A. (2019). Pathogenesis and Consequences of Disordered Sleep in PCOS. Clinical medicine insights. Reproductive health, 131179558119871269. https://doi.org/10.1177/1179558119871269
Sam, Susan, and Ehrmann, David A. "Pathogenesis and Consequences of Disordered Sleep in PCOS." Clinical medicine insights. Reproductive health vol. 13 (2019): 1179558119871269. doi: https://doi.org/10.1177/1179558119871269
Sam S, Ehrmann DA. Pathogenesis and Consequences of Disordered Sleep in PCOS. Clin Med Insights Reprod Health. 2019 Sep 03;13:1179558119871269. doi: 10.1177/1179558119871269. eCollection 2019. PMID: 31516314; PMCID: PMC6724486.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries